Researchers from CJ Bioscience Inc. presented the discovery and preclinical characterization of CJRB-201, a novel microbiome-based therapy for the treatment of inflammatory bowel disease (IBD).
Microbiome-modulating therapies are increasingly being explored to treat a variety of diseases. However, the market is still in its infancy and a lack of solid regulations remains challenging for companies to overcome, speakers at the BioKorea 2022 said May 11.
Microbiome-modulating therapies are increasingly being explored to treat a variety of diseases. However, the market is still in its infancy and a lack of solid regulations remains challenging for companies to overcome, speakers at the BioKorea 2022 said May 11.
